Navigation Links
Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
Date:8/29/2012

IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The conference is one of several events organized by Agendia throughout the year that brings together research scientists and physicians in clinical practice dedicated to the use and development of molecular diagnostics for cancer treatment.

"Events like these demonstrate why it is an exciting time in the field of medical oncology," said Dr. Stefan Gluck, Chairman of Agendia's Medical Advisory Board. "Breakthrough tools in molecular diagnostics, such as Agendia's MammaPrint, BluePrint and ColoPrint, play an integral role in helping physicians make clinical decisions about how to most effectively treat their patients. Most importantly, these tools are only the beginning of the precision medicine revolution."

The event featured an impressive list of speakers and panels on the following topics:

The Science Behind Genomic Based Analysis of Breast Cancer

  • Rene Bernards, PhD
    Chief Scientific Officer and Co-Founder, Agendia

Clinical Utility of Molecular Diagnostics

  • Ralph V. Boccia, MD, FACP
    Clinical Associate Professor of Medicine, Georgetown University

Landmark Clinical Trials

  • Stefan Gluck, MD, FRCP(C), PhD
    Sylvester Professor, Miller School of Medicine, University of Miami

Tumor Round Table Discussion and Case Study Review

  • Stephanie Akbari, MD, FACS (Moderator)
    Medical Director, Center for Breast Health, Virginia Hospital Center
  • Mark A. Gittleman, MD, FACS
    Medical Director, Breast Care Specialists and Advanced Breast Care Imaging
  • Stefan Gluck, MD, PhD
    Sylvester Professor, Miller School of Medicine, University of Miami
  • James V. Pellicane, MD, FACS
    Director, Breast Oncology, Bon Secours Cancer Institute
  • Jamie Shutter, MD
    Owner, South Beach Medical Consultants
  • Hatem Soliman, MD
    Assistant Member, Comprehensive Breast Cancer and Experimental Therapeutics, Moffitt Cancer Center and Research Institute

"Seventy five percent of cancer therapies today are ineffective," said David Macdonald, CEO of Agendia. "This represents 37 billion dollars spent globally on cancer drugs that do not benefit patients. Today's event further demonstrates Agendia's commitment to the continued development of clinically reliable diagnostics that provide doctors with decision-making tools needed to improve the effectiveness of cancer therapies for their patients."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact:
Post+Beam
Melissa Hurley
Tel: +1 646 442 2773
E-mail: hurley@postandbeam.is


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Power Wheelchair Brings Independence and Hope to Man with Complications Due to Spina Bifida
5. Transitions Optical Brings Importance Of Healthy, Enhanced Vision Into Focus By Taking National Sightseeing City Tour To Chicago And Announcing The Citys Top 10 Sights To See
6. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
7. Cardinal Health Brings Resolution to Litigation with DEA Settlement
8. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
9. Latest Breakthroughs and Treatments in Spinal Cord Injury Medicine Bring Top Clinicians and Researchers Together in Las Vegas
10. New Program Has Doctors, Patients Learn Together As Traditional Relationship Changes Forever
11. SuccessEHS "Forward Together" Customer Conference Begins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ ... full service medical device development firm, announced today that ... Toronto -based medical device industrial design and ... medtech companies throughout North America ... medical device talent spanning the design, engineering, regulatory, and ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City ... holidays (IBT World Travel Trends Report). As travelers visit both urban destinations, they ... temperatures, and prolonged sun exposure. In response, the outdoor industry has blurred the ...
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
Breaking Medicine News(10 mins):